Skip to content
ClinCalc Pro
Menu
Intranasal Corticosteroid Pregnancy: 'There are no or limited amount of data from the use of mometasone furoate in pregnant women. Studies in animals have shown reproductive toxicity. As with other nasal corticosteroid preparations, NASONEX Nasal Spray should not be used in pregnancy unless the potential benefit to the mother justifies any potential risk to the mother, foetus or infant. Infants born of mothers who received corticosteroids during pregnancy should be observed carefully for hypoadrenalism.' Lactation: excretion in human milk is unknown — 'a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from NASONEX Nasal Spray therapy'. Fertility: no clinical data; animal studies showed reproductive toxicity but no effects on fertility.

Mometasone Nasal Spray

Brand names: Nasonex, Clarinaze (with loratadine)

Mometasone furoate nasal spray is an intranasal corticosteroid used for allergic rhinitis and as a component of nasal polyp management, delivering anti-inflammatory steroid directly to the nasal mucosa with minimal systemic exposure.

Adult dose

Dose: Seasonal allergic or perennial rhinitis, adults (including older patients) and children 12 years and over: two actuations (50 micrograms per actuation) in each nostril once daily — total dose 200 micrograms daily
Route: intranasal
Frequency: once daily; once symptoms are controlled, reduce to one actuation in each nostril (total dose 100 micrograms) for maintenance
Max: 400 micrograms daily for allergic rhinitis (four actuations in each nostril once daily), with dose reduction recommended following control of symptoms
SCOPE: this dose is for allergic rhinitis, the page's primary indication. The same SPC also covers NASAL POLYPOSIS: 'The usual recommended starting dose for polyposis is two actuations (50 micrograms/actuation) in each nostril once daily (total daily dose of 200 micrograms). If after 5 to 6 weeks symptoms are inadequately controlled, the dose may be increased to a daily dose of two sprays in each nostril twice daily (total daily dose of 400 micrograms). The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. If no improvement in symptoms is seen after 5 to 6 weeks of twice daily administration, the patient should be re-evaluated and treatment strategy reconsidered.' Efficacy and safety studies in nasal polyposis were four months in duration. VERBATIM RHINITIS POSOLOGY: 'Adults (including older patients) and children 12 years of age and older: The usual recommended dose is two actuations (50 micrograms/actuation) in each nostril once daily (total dose 200 micrograms). Once symptoms are controlled, dose reduction to one actuation in each nostril (total dose 100 micrograms) may be effective for maintenance. If symptoms are inadequately controlled, the dose may be increased to a maximum daily dose of four actuations in each nostril once daily (total dose 400 micrograms). Dose reduction is recommended following control of symptoms.' ONSET: 'a clinically significant onset of action within 12 hours after the first dose in some patients with seasonal allergic rhinitis; however, full benefit of treatment may not be achieved in the first 48 hours. Therefore, the patient should continue regular use to achieve full therapeutic benefit.' Treatment may need to start some days before the expected start of the pollen season in patients with a history of moderate to severe seasonal symptoms. DEVICE PRIMING: 'Prior to administration of the first dose, shake container well and actuate the pump 10 times (until a uniform spray is obtained). If the pump is not used for 14 days or longer, reprime the pump with 2 actuations until a uniform spray is observed, before next use. Shake container well before each use. The bottle should be discarded after the labelled number of actuations or within 2 months of first use.' EACH ACTUATION 'delivers approximately 100 mg of mometasone furoate suspension, containing mometasone furoate monohydrate equivalent to 50 micrograms mometasone furoate'. NOT COVERED BY THIS SOURCE: the mometasone-with-loratadine combination spray (Clarinaze) listed among this page's brands has its own licence and is not described by this SPC. Some sections of the product information we used were incomplete — check the full SPC.

Paediatric dose

Dose: Seasonal allergic or perennial rhinitis, children 3 to 11 years: one actuation (50 micrograms per actuation) in each nostril once daily — total dose 100 micrograms daily
Route: intranasal
Frequency: once daily
Max: 100 micrograms daily (one actuation in each nostril once daily) — no higher dose is given in this SPC for the 3 to 11 year age band
NOT A PER-KG DOSE — dosePerKg is deliberately null; this is a fixed actuation count, not a weight-based dose. VERBATIM SPC 4.2: 'Children between the ages of 3 and 11 years: The usual recommended dose is one actuation (50 micrograms/actuation) in each nostril once daily (total dose 100 micrograms).' AGE LIMITS, verbatim: 'Seasonal Allergic Rhinitis and Perennial Rhinitis — The safety and efficacy of NASONEX Nasal Spray in children under 3 years of age have not been established. Nasal Polyposis — The safety and efficacy of NASONEX Nasal Spray in children and adolescents under 18 years of age have not been established.' So there is NO paediatric polyposis dose in this label. Section 4.4 warns that potential systemic effects of nasal corticosteroids include growth retardation in children and adolescents, and psychological or behavioural effects particularly in children. Verify paediatric use against a children's formulary.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance, mometasone furoate, or to any of the excipients
  • Should not be used in the presence of untreated localised infection involving the nasal mucosa, such as herpes simplex
  • Patients who have experienced recent nasal surgery or trauma should not use a nasal corticosteroid until healing has occurred, because of the inhibitory effect of corticosteroids on wound healing

Side effects

  • Very common: epistaxis (recorded for twice daily dosing for nasal polyposis); throat irritation (twice daily polyposis dosing)
  • Common: epistaxis — generally self-limiting and mild, 5% in allergic rhinitis studies versus up to 15% for the active control nasal corticosteroids
  • Common: pharyngitis; headache
  • Common: nasal burning, nasal irritation
  • Not known: hypersensitivity including anaphylactic reactions, angioedema, bronchospasm and dyspnoea
  • Not known: glaucoma, increased intraocular pressure, cataracts, vision blurred
  • Not known: nasal ulceration, nasal septum perforation
  • Not known: disturbances of taste and smell
  • Upper respiratory tract infection (uncommon with twice daily polyposis dosing)
  • Paediatric population: adverse events in clinical studies — epistaxis (6%), headache (3%), nasal irritation (2%) and sneezing (2%) — were comparable to placebo

Monitoring

  • SPC 4.4: 'patients using NASONEX Nasal Spray over several months or longer should be examined periodically for possible changes in the nasal mucosa. If localised fungal infection of the nose or pharynx develops, discontinuance of NASONEX Nasal Spray therapy or appropriate treatment may be required. Persistence of nasopharyngeal irritation may be an indication for discontinuing' treatment.
  • SPC 4.4: 'Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods... Potential systemic effects may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).'
  • SPC 4.4: 'Following the use of intranasal corticosteroids, instances of increased intraocular pressure have been reported.' If a patient reports blurred vision or other visual disturbance, consider referral to an ophthalmologist for possible cataract, glaucoma or central serous chorioretinopathy.
  • Use with caution, if at all, in active or quiescent tuberculous infection of the respiratory tract, or untreated fungal, bacterial or systemic viral infections. Warn potentially immunosuppressed patients about exposure to chickenpox and measles.
  • Not recommended in nasal septum perforation.
  • Contains benzalkonium chloride, which 'may cause irritation or swelling inside the nose, especially if used for a long time'.
  • Nasal polyposis: re-evaluate at 5 to 6 weeks if symptoms are inadequately controlled, and again if there is no improvement after 5 to 6 weeks of twice daily dosing.
  • This list may be incomplete — check the full SPC.

Clinical monograph

How it works

Mometasone is a potent topical glucocorticoid that acts on nasal mucosal cells to suppress inflammatory mediator release and reduce mucosal oedema, easing congestion, rhinorrhoea and sneezing.

Prescribing in practice

  • Correct technique — aiming the spray away from the nasal septum — reduces the risk of epistaxis, nasal irritation and, rarely, septal perforation with prolonged use.
  • Full benefit develops over days of regular use, so it should be taken continuously rather than as required during the relevant season.
  • Long-term use, particularly alongside inhaled or other corticosteroids, warrants awareness of cumulative steroid load and, in children, periodic height monitoring.

Monitoring

Periodically check inhalation/intranasal technique and inspect for nasal irritation or bleeding, and monitor growth in children on prolonged treatment.

Counselling the patient

  • Use it every day as prescribed; it may take several days to work fully.
  • Aim the nozzle slightly outward, away from the middle wall of the nose, to reduce nosebleeds.
  • Tell your clinician about persistent nosebleeds, crusting or a whistling sound when breathing.

Evidence & guidelines

Intranasal mometasone is a guideline-recommended first-line treatment for moderate-to-severe allergic rhinitis and is established in nasal polyp care, supported by NICE and the SPC.

Reference: NICE NG174; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.